#United States #Eisai #Nutley #Narcolepsy #E2086

Eisai's New Phase 2 Study for Narcolepsy

Eisai Inc., based in Nutley, New Jersey, has announced the initiation of patient enrollment for their global clinical trial Study E2086-G000-202, also known as Study 202. This clinical study aims to investigate the efficacy, safety, and tolerability of E2086, a novel selective orexin-2 receptor agonist, for adults diagnosed with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).

Understanding Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness and unexpected episodes of sleep. This condition arises from the disruption of the sleep/wakefulness cycle, primarily linked to the deficiency of the neurotransmitter orexin. NT1, associated with low orexin levels, leads to severe daytime drowsiness and cataplexy episodes, where a person may suddenly lose muscle tone. On the other hand, NT2 patients experience excessive sleepiness without these sudden muscle relaxations.

The Clinical Study Outline

Study 202 is designed as a multi-period, dose escalation study. Participants with NT1 or NT2 will receive various doses of E2086, with some being assessed against a placebo. The objective is to evaluate the drug’s effects on wakefulness through both objective metrics and subjective patient-reported outcomes. Notably, this study has been registered on ClinicalTrials.gov under the identifier NCT07493265, with study sites set to emerge across Canada, China, Europe, Japan, and South Korea.

E2086's Promising Potential

E2086 has demonstrated clinical promise in previous studies. Nonclinical trials suggest that this new medication may enhance wakefulness, potentially reversing the symptoms associated with narcolepsy. In a recently completed proof-of-mechanism study involving NT1 patients, E2086 showed statistically significant improvements in wakefulness compared to both placebo and the commonly prescribed modafinil. Such findings emphasize the potential of E2086 to provide better outcomes for individuals suffering from this debilitating condition.

What Lies Ahead?

Eisai is committed to addressing the unmet needs within the healthcare sector. The company emphasizes the importance of the patient’s perspective in medicine development, which drives them to innovate and bring therapies like E2086 to those who need them urgently. With the trial officially launched, the Eisai team continues to recruit participants and gather data that could affirm E2086 as a viable treatment option for narcolepsy.

For those interested in this study, Eisai Medical Information is available for inquiries through their official website or via a toll-free number.

About Eisai Inc.

Eisai Inc. operates as a subsidiary of Tokyo-based Eisai Co., Ltd. The company focuses on researching and developing treatments for neurodegenerative conditions, including cancer and Alzheimer’s disease. Guided by the primary aim of enhancing the quality of life for patients and their families, Eisai continues to pioneer in creating effective healthcare solutions worldwide.